arrow
P

Preetesh Jain

university of texas health san antonio
H指数:47
被引数:7,731

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

SMART START试验的长期临床结果:利妥昔单抗、来那度胺和伊布替尼在 newly diagnosed large B-cell lymphoma 患者中的应用

2026-07-020
OAAI
BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance

BRG1介导的铁死亡抑制是BTK抑制剂耐药性的基础

2026-07-020
OAAI
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

套细胞淋巴瘤在序贯一线 bendamustine-rituximab 和二线 Bruton 酪氨酸激酶抑制剂治疗后的预后

2026-04-250
OAAI
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

TCA循环模式切换决定了套细胞淋巴瘤中耐普拉替诺的持续存在细胞的命运

Blood
IF23.1
2025-07-250
OAAI
Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

CAR-T疗法后疾病进展的复发或难治性套细胞淋巴瘤患者的治疗方案与结局:一项多中心分析

BLOOD
IF23.1
2024-11-050
PRE
Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma (vol 12, 2877, 2021)
2024-10-070
OAAI
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study

免疫效应细胞治疗后针对白喉、破伤风和肺炎球菌的体液免疫和抗体反应: 一项前瞻性研究

2024-09-190
OAAI
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs
2024-09-110
OAAI
Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial
2024-07-014
PRE
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors
2023-07-2010
OAAI
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
2023-03-1382
OA